Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daisuke Gotoh

Showing results (151-160 of 153) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 153 results.
International Journal of Clinical Oncology|June 18, 2024
Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohortMakito Miyake, Nobutaka Nishimura, Yuki Oda, et al.
Japanese Journal of Clinical Oncology|December 7, 2023
Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohortMakito Miyake, Nobutaka Nishimura, Yuki Oda, et al.
Cancers|April 12, 2022
Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective StudyTakuto Shimizu, Makito Miyake, Nobutaka Nishimura, et al.
Pageof 16

Showing results (151-160 of 153) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 153 results.
International Journal of Clinical Oncology|June 18, 2024
Difference of oncological efficacy between two immune checkpoint inhibitors following first-line platinum-based chemotherapy in patients with unresectable, metastatic, advanced urothelial carcinoma: a multicenter real-world Japanese cohortMakito Miyake, Nobutaka Nishimura, Yuki Oda, et al.
Japanese Journal of Clinical Oncology|December 7, 2023
Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohortMakito Miyake, Nobutaka Nishimura, Yuki Oda, et al.
Cancers|April 12, 2022
Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective StudyTakuto Shimizu, Makito Miyake, Nobutaka Nishimura, et al.
Pageof 16